North America Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

North America Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030


The North America Guillain-Barre Syndrome Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030).

The US market dominated the North America Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $211,863.5 Thousands by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).

The aging population has a significant impact on GBS. It primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population continues to age, there is a natural increase in the number of people at risk for GBS, contributing to the overall burden of the disease.

Additionally, by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country’s total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals.

As per the Government of Canada, in 2023, the government announced an investment of $196.1 billion over ten years, including $46.2 billion in new funding, for provinces and territories to improve health care services for Canadians. In addition, it will invest $2.5 billion over ten years to support indigenous priorities and complementary federal support, for a total of $198.6 billion over ten years.

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • PTC, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
North America Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics
  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Others
By Route Of Administration
  • Parenteral
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Guillain-Barre Syndrome Market, by Therapeutics
1.4.2 North America Guillain-Barre Syndrome Market, by Route Of Administration
1.4.3 North America Guillain-Barre Syndrome Market, by Distribution Channel
1.4.4 North America Guillain-Barre Syndrome Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. North America Guillain-Barre Syndrome Market by Therapeutics
4.1 North America Intravenous Immunoglobulin Market by Country
4.2 North America Plasma Exchange Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Guillain-Barre Syndrome Market by Route Of Administration
5.1 North America Parenteral Market by Country
5.2 North America Oral Market by Country
Chapter 6. North America Guillain-Barre Syndrome Market by Distribution Channel
6.1 North America Hospital Pharmacies Market by Country
6.2 North America Retail Pharmacies Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Guillain-Barre Syndrome Market by Country
7.1 US Guillain-Barre Syndrome Market
7.1.1 US Guillain-Barre Syndrome Market by Therapeutics
7.1.2 US Guillain-Barre Syndrome Market by Route Of Administration
7.1.3 US Guillain-Barre Syndrome Market by Distribution Channel
7.2 Canada Guillain-Barre Syndrome Market
7.2.1 Canada Guillain-Barre Syndrome Market by Therapeutics
7.2.2 Canada Guillain-Barre Syndrome Market by Route Of Administration
7.2.3 Canada Guillain-Barre Syndrome Market by Distribution Channel
7.3 Mexico Guillain-Barre Syndrome Market
7.3.1 Mexico Guillain-Barre Syndrome Market by Therapeutics
7.3.2 Mexico Guillain-Barre Syndrome Market by Route Of Administration
7.3.3 Mexico Guillain-Barre Syndrome Market by Distribution Channel
7.4 Rest of North America Guillain-Barre Syndrome Market
7.4.1 Rest of North America Guillain-Barre Syndrome Market by Therapeutics
7.4.2 Rest of North America Guillain-Barre Syndrome Market by Route Of Administration
7.4.3 Rest of North America Guillain-Barre Syndrome Market by Distribution Channel
Chapter 8. Company Profiles
8.1 F. Hoffmann-La Roche Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 PTC, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.6 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Takeda Pharmaceutical Company Limited
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.6 SWOT Analysis
8.10. Bristol Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings